Degarelix
- Generic Name
- Degarelix
- Brand Names
- Firmagon, Degarelix Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C82H103ClN18O16
- CAS Number
- 214766-78-6
- Unique Ingredient Identifier
- SX0XJI3A11
- Background
Degarelix is used for the treatment of advanced prostate cancer. Degarelix is a synthetic peptide derivative drug which binds to gonadotropin-releasing hormone (GnRH) receptors in the pituitary gland and blocks interaction with GnRH. This antagonism reduces luteinising hormone (LH) and follicle-stimulating hormone (FSH) which ultimately causes testosterone suppression. Reduction in testosterone is important in treating men with advanced prostate cancer. Chemically, it is a synthetic linear decapeptide amide with seven unnatural amino acids, five of which are D-amino acids. FDA approved on December 24, 2008.
- Indication
Degaralix is used for the management of advanced prostate cancer.
- Associated Conditions
- Advanced Prostate Cancer
A Comparative Study of Degarelix Three-month Depot in Three Different Dosing Regimens in Patients With Prostate Cancer
- First Posted Date
- 2005-07-01
- Last Posted Date
- 2010-12-10
- Lead Sponsor
- Ferring Pharmaceuticals
- Target Recruit Count
- 460
- Registration Number
- NCT00116753
- Locations
- 🇺🇸
SW Florida Urological Associates, Fort Myers, Florida, United States
🇺🇸Regional Urology, Shreveport, Louisiana, United States
🇨🇦The Male Health Center, Toronto, Ontario, Canada
A Parallel Group Comparison of the Efficacy and Safety of Degarelix at Two Different Dosing Regimens in Patients With Prostate Cancer
- First Posted Date
- 2005-07-01
- Last Posted Date
- 2011-12-19
- Lead Sponsor
- Ferring Pharmaceuticals
- Target Recruit Count
- 127
- Registration Number
- NCT00116779
- Locations
- 🇺🇸
Advanced Urology Medical Center, Anaheim, California, United States
🇺🇸Pacific Clinical Research, Santa Monica, California, United States
🇺🇸South Florida Medical Research, Aventura, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.